Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Intensive blood pressure lowering cuts heart failure, death: study

Lowering blood pressure below a commonly used target dramatically reduced heart failure and risk of death in adults aged 50 and older in a large U.S. government-sponsored study, results that could lead to a change in treatment guidelines and medical practice.   The data presented on Monday had some potentially troubling side effects that researchers […]

Read More »

Lilly diabetes drug cuts heart failure death, hospitalization: study

Eli Lilly’s new diabetes drug Jardiance significantly cut the risk of heart-related death and hospitalization for heart failure in patients with type 2 diabetes who are at high risk for serious heart problems, according to data from a large study presented on Monday. The 3-year trial of more than 7,000 patients caused a sensation in […]

Read More »

U.S. top court allows Apotex to pursue generic version of Daiichi drug

The U.S. Supreme Court on Monday rejected appeals by Daiichi Sankyo Inc and Mylan Pharmaceuticals Inc seeking to stop Apotex Inc from trying to introduce a generic version of Benicar, a drug for treating hypertension. The justices declined to review an April ruling by the U.S. Court of Appeals for the Federal Circuit in favor […]

Read More »

Novo Nordisk diabetes drug fails to help heart failure: study

The Novo Nordisk diabetes drug Victoza failed to improve clinical stability or delay death in patients suffering from advanced heart failure, researchers reported at a medical meeting on Sunday. The injectable drug, known chemically as liraglutide, was tested in 300 patients with and without type 2 diabetes who had advanced heart failure and a recent […]

Read More »

FDA panel backs Merck & Co. drug to reverse muscle relaxant effect

Merck & Co’s drug to reverse the effects of muscle relaxants used in surgery is safe and effective enough to warrant approval, an independent panel to the U.S. Food and Drug Administration said. The drug, which goes by the chemical name of sugammadex, has repeatedly been rejected by the FDA due to concerns about potentially […]

Read More »

Allergan CEO Saunders warms up to drug discovery

Brenton Saunders, the whiz-kid pharmaceutical executive with a reputation for being wary of the costs of early-stage drug development, says he’s open to new ideas from outside and is now warming up to investing in drug discovery if it makes sense for his company. That could ease concern that if Allergan Inc’s “friendly” talks with […]

Read More »

FDA approves Gilead Sciences’ HIV drug cocktail

Gilead Sciences Inc said the U.S. Food and Drug Administration had approved its HIV drug cocktail, Genvoya, to treat patients aged 12 and above. Genvoya, a combination tablet approved as a complete regimen, is designed to treat previously untreated patients weighing at least 35 kilograms (77 pounds), the FDA said on Thursday. (1.usa.gov/1RYxl7t) The drug […]

Read More »

Gilead’s Blockbuster Sovaldi Linked to Slower Heartbeats and Puts Patients at Risk of Passing Out

NEW YORK – A team of French doctors reported Gilead Sciences, Inc. (GILD)’s blockbuster hepatitis C drug Sovaldi can cause abnormally slower heart rates in patients taking the medication. The slower heartbeats can cause patients to pass out, the doctors said in a letter to The New England Journal of Medicine. According to the French […]

Read More »

China launches pilot scheme to ease drug approvals

China has launched a three-year pilot scheme to loosen approvals for new drugs, the country’s food and drug regulator said on Thursday, as Beijing looks to help stimulate innovation in the country’s pharmaceutical sector. The trial, set to take place in 10 regions, will allow research and development bodies to seek drug approvals, which are […]

Read More »

AstraZeneca, Teva reach deal with states in Medicaid pricing case

Drugmakers AstraZeneca Plc and Cephalon, a unit of Teva Pharmaceutical Industries Ltd, reached a multistate accord on Wednesday over civil charges they overbilled state Medicaid programs, the New York Attorney General announced. The settlement with the states comes after the U.S. Justice Department settled parallel civil charges with both companies in July. The $54 million […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom